Cover Image
市場調查報告書

Supernus Pharmaceuticals, Inc.:產品平台分析

Supernus Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 240940
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
Supernus Pharmaceuticals, Inc.:產品平台分析 Supernus Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 25 Pages
簡介

Supernus Pharmaceuticals, Inc.是專門開發中樞神經疾病用治療藥並商品化的製藥公司。該公司產品可用於針對部分發作的輔助治療、原發性強直性癲癇發作的早期單劑療法,以及相關的腸漏症候群的輔助治療等。

本報告提供Supernus Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Supernus Pharmaceuticals, Inc.的基本資料

  • Supernus Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Supernus Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Supernus Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Supernus Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
  • IND/CTA 被申請了的產品/聯合治療模式

Supernus Pharmaceuticals, Inc.:藥物簡介

  • molindone hydrochloride ER
  • viloxazine hydrochloride
  • SPN-809

Supernus Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Supernus Pharmaceuticals, Inc.:最近的開發平台趨勢

Supernus Pharmaceuticals, Inc.:暫停中的計劃

Supernus Pharmaceuticals, Inc.:企業發表

Supernus Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07084CDB

Summary

Global Markets Direct's, 'Supernus Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Supernus Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Supernus Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Supernus Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Supernus Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Supernus Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Supernus Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Supernus Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Supernus Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Supernus Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Supernus Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Supernus Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Supernus Pharmaceuticals, Inc. Snapshot
    • Supernus Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Supernus Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Supernus Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Supernus Pharmaceuticals, Inc. - Pipeline Products Glance
    • Supernus Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Supernus Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
  • Supernus Pharmaceuticals, Inc. - Drug Profiles
    • molindone hydrochloride ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • viloxazine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPN-809
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Supernus Pharmaceuticals, Inc. - Pipeline Analysis
    • Supernus Pharmaceuticals, Inc. - Pipeline Products by Target
    • Supernus Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Supernus Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Supernus Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Supernus Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Supernus Pharmaceuticals, Inc. - Dormant Projects
  • Supernus Pharmaceuticals, Inc. - Company Statement
  • Supernus Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Supernus Pharmaceuticals, Inc., Key Information
  • Supernus Pharmaceuticals, Inc., Key Facts
  • Supernus Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Supernus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Supernus Pharmaceuticals, Inc. - Phase II, 2015
  • Supernus Pharmaceuticals, Inc. - IND/CTA Filed, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Supernus Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Supernus Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Supernus Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Supernus Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Supernus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Supernus Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top